Crinetics Pharmaceuticals, Inc. (CRNX): Price and Financial Metrics

Crinetics Pharmaceuticals, Inc. (CRNX)

Today's Latest Price: $14.00 USD

0.52 (3.86%)

Updated Apr 2 2:22pm

Add CRNX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CRNX Stock Summary

  • Crinetics Pharmaceuticals Inc's stock had its IPO on July 18, 2018, making it an older stock than just 2.75% of US equities in our set.
  • CRNX's price/sales ratio is 301.89; that's higher than the P/S ratio of 99.16% of US stocks.
  • Revenue growth over the past 12 months for Crinetics Pharmaceuticals Inc comes in at -50.86%, a number that bests only 3.38% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Crinetics Pharmaceuticals Inc, a group of peers worth examining would be CNCE, QURE, INO, SNDX, and ADAP.
  • Visit CRNX's SEC page to see the company's official filings. To visit the company's web site, go to
CRNX Daily Price Range
CRNX 52-Week Price Range

CRNX Stock Price Chart More Charts

CRNX Price/Volume Stats

Current price $14.00 52-week high $28.81
Prev. close $13.48 52-week low $10.63
Day low $13.45 Volume 14,456
Day high $15.06 Avg. volume 65,945
50-day MA $18.98 Dividend yield N/A
200-day MA $19.77 Market Cap 343.94M

Crinetics Pharmaceuticals, Inc. (CRNX) Company Bio

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is based in San Diego, California.

CRNX Latest News Stream

Event/TimeNews Detail
Loading, please wait...

CRNX Latest Social Stream

Loading social stream, please wait...

View Full CRNX Social Stream

CRNX Price Returns

1-mo -28.43%
3-mo -45.21%
6-mo -15.61%
1-year -39.71%
3-year N/A
5-year N/A
YTD -44.20%
2019 -16.34%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0464 seconds.